Alphabetical listing of all products

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Prices
  • 5 mg - 280 EUR
  • 25 mg - 1120 EUR
  • 100 mg - 3360 EUR

TG02

TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3; IC50 values are 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively. TG02 is cytotoxic in a broad range of tumor cell lines, inducing G1 cell cycle arrest, both the intrinsic and extrinsic pathways of apoptosis, depletion of XIAP and the key multiple myeloma survival protein Mcl-1. It is currently undergoing clinical trials in advanced leukemias and multiple myeloma.

catalogue number: T169
synonyms: SB1317, SB-1317
CAS: 937270-47-8
MW: 372.47 g/mol

References
Leukemia. 2012 Feb;26(2):236-43. PMID: 21860433
J Med Chem. 2012 Jan 12;55(1):169-96. PMID: 22148278
Clin Cancer Res. 2013 Mar 26. [Epub ahead of print] PMID: 23532886